| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.023 | 0.6 |